Vyepti

Vyepti (eptinezumab) is an intravenous infusion used for migraine prevention in adults. This calcitonin gene-related peptide (CGRP) inhibitor helps reduce the frequency of migraine attacks. It is administered by healthcare professionals in clinical settings. Eptinezumab is not intended for acute migraine treatment.

Vyepti is prescribed to prevent episodic or chronic migraines in adults. It works by blocking CGRP, a protein involved in migraine pain pathways. Patients with frequent migraines may benefit from this preventive therapy. It is designed for long-term use to reduce attack frequency rather than treat symptoms during an episode.

After receiving Vyepti, some patients report fewer and less severe migraine days over time. Common effects may include mild reactions at the infusion site, such as redness or discomfort. Most individuals tolerate the treatment well, though individual responses vary. Regular administration may help improve daily functioning for those with chronic migraines.

Vyepti should be administered by a healthcare provider in a controlled setting. Patients should disclose all medications and medical conditions before treatment. Infusion reactions, though rare, may occur; monitoring is recommended during and after administration. It is not suitable for treating acute migraine attacks once they begin.

Limited data exist on drug interactions with Vyepti, as it is a monoclonal antibody. No significant interactions with common medications like pain relievers or preventive treatments have been reported. However, patients should inform their provider about all current medications. Live vaccines should be avoided during treatment unless approved by a doctor.